


ETCTN Trials by Disease/Treatment Area: Neuroendocrine/Endocrine



ETCTN Neuroendocrine/Endocrine Cancer Trials (Open as of 3/10/2025)

<b>Protocol Number</b>	<b>Phase</b>	<b>Protocol Title</b>
<b>10487</b>	II	A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation
<b>10558</b>	II	A phase II randomized control trial of triapine plus lutetium 177 dotatate versus lutetum 177 dotatate alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors
<b>10479</b>	I	A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors